ofranergene obadenovec

AXP000145.1 · Viral vector gene therapy

Platform
adenovirus (Ad5, non-replicating, PPE-1-3x endothelial promoter)
Originator
Vascular Biogenics (VBL Therapeutics)
Sponsor
Notable Labs

Names

NameTypeSource
ofranergene obadenovecpreferred name, INNcurator, ncit
Ofra-Vecbrandpress
VB-111codencit
GT-111 ambiguousformer codencit

Virus

Role
In vivo gene transfer
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5
Replication
non replicating
Modifications
non-replicating Ad5; modified murine PPE-1 promoter with three endothelium-specific enhancer copies and a hypoxia-responsive element
Transgenes
Fas-chimera (TNFRSF1A-FAS fusion)
Route
intravenous
Source
evidence

Cross-references

NCI Thesaurus
C71539
FDA UNII
5Q5PRH05GI

Approvals

No regulatory approval recorded.

Clinical trials (7)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04166383VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)TerminatedPhase 22020-08-092022-04-1214Colorectal Cancer With Hepatic Metastases; Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumors; Metastatic Colorectal Cancer
NCT04406272VB-111 in Surgically Accessible Recurrent/Progressive GBMTerminatedPhase 22020-08-012024-08-0115Glioblastoma; Recurrent Glioblastoma
NCT03398655A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)CompletedPhase 32017-12-192022-07-19408Recurrent Platinum Resistant Ovarian Cancer
NCT02511405A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)CompletedPhase 32015-082017-11-03252Glioblastoma
NCT01260506Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma MultiformeCompletedPhase 1/22010-122015-07-2375Glioblastoma Multiforme
NCT01229865Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid CancerCompletedPhase 22010-122014-1029Differential Thyroid Cancer
NCT00559117A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic CancerUnknownPhase 12007-112015-0648Advanced and/or Metastatic Solid Organ Cancer
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT01711970A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian CancerCompletedPhase 1/22012-112017-05-0338Platinum Resistant Ovarian Cancername in title: VB-111

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 37906726Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).Journal of clinical oncology : official journal of the American Society of Clinical Oncology2024cited by trial NCT03398655
PMID 38184304VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial.Journal for immunotherapy of cancer2024cited by trial NCT04166383
PMID 37540556Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research2023cited by trial NCT02511405
PMID 33637348Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.Gynecologic oncology2021cited by trial NCT03398655
PMID 31844886Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study.Neuro-oncology2020name in title: VB-111
PMID 31844890A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).Neuro-oncology2020cited by trial NCT02511405
PMID 32265057Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.Gynecologic oncology2020name in title: ofranergene obadenovec
PMID 23589178Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.Clinical cancer research : an official journal of the American Association for Cancer Research2013name in title: VB-111

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 34377989Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.Neuro-oncology advances2021name in title: VB-111
PMID 26108658VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme.Journal of neuro-oncology2015name in title: VB-111
PMID 21961496VB-111 for cancer.Expert opinion on biological therapy2011name in title: VB-111
PMID 22701765Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models.Genes & cancer2011name in title: VB-111
Unconfirmed matches (2)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 34973444Efficacy and Safety of Bevacizumab Combined with Other Therapeutic Regimens for Treatment of Recurrent Glioblastoma: A Network Meta-analysis.World neurosurgery2022name in abstract: VB-111
PMID 20506053American association for cancer research - 101st annual meeting - investigating new therapeutic candidates: part 2.IDrugs : the investigational drugs journal2010name in abstract: VB-111

NIH grants

No confirmed grants yet.

Unconfirmed matches (1)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

ProjectTitleOrganisationPIYearsLinked by
ZIABC011343Clinical protocols for the treatment of gastrointestinal cancerDIVISION OF BASIC SCIENCES - NCIGRETEN, TIM2019–2023name in abstract: VB-111

Notes

VB-111: non-replicating Ad5 in which a modified murine pre-proendothelin-1 promoter (PPE-1-3x, with a hypoxia-responsive element) drives a Fas-chimera transgene (TNFR1 extracellular and transmembrane domains fused to the Fas intracellular death domain), to kill angiogenic tumour endothelium. Given intravenously. Phase 3 OVAL in platinum-resistant ovarian cancer did not show benefit; earlier phase 3 in recurrent glioblastoma (GLOBE) also failed.

How to cite

ofranergene obadenovec (AXP000145.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000145.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.